BI 6015HNF4α antagonist CAS# 93987-29-2 |
- Ro3280
Catalog No.:BCC3962
CAS No.:1062243-51-9
- MLN0905
Catalog No.:BCC3961
CAS No.:1228960-69-7
- Rigosertib
Catalog No.:BCC4296
CAS No.:592542-59-1
- Rigosertib sodium
Catalog No.:BCC4067
CAS No.:592542-60-4
- GSK461364
Catalog No.:BCC3788
CAS No.:929095-18-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 93987-29-2 | SDF | Download SDF |
PubChem ID | 3269393 | Appearance | Powder |
Formula | C15H13N3O4S | M.Wt | 331.35 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 20 mM in DMSO | ||
Chemical Name | 2-methyl-1-(2-methyl-5-nitrophenyl)sulfonylbenzimidazole | ||
SMILES | CC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)N2C(=NC3=CC=CC=C32)C | ||
Standard InChIKey | ILVCPQPMRPHZSG-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C15H13N3O4S/c1-10-7-8-12(18(19)20)9-15(10)23(21,22)17-11(2)16-13-5-3-4-6-14(13)17/h3-9H,1-2H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Hepatocyte nuclear factor 4α (HNF4α) antagonist. Represses expression of known HNF4α target genes. Decreases HNF4α DNA binding. Exhibits cytotoxic activity in a range of tumor cell lines, including human hepatocellular carcinoma. |
BI 6015 Dilution Calculator
BI 6015 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.018 mL | 15.0898 mL | 30.1796 mL | 60.3591 mL | 75.4489 mL |
5 mM | 0.6036 mL | 3.018 mL | 6.0359 mL | 12.0718 mL | 15.0898 mL |
10 mM | 0.3018 mL | 1.509 mL | 3.018 mL | 6.0359 mL | 7.5449 mL |
50 mM | 0.0604 mL | 0.3018 mL | 0.6036 mL | 1.2072 mL | 1.509 mL |
100 mM | 0.0302 mL | 0.1509 mL | 0.3018 mL | 0.6036 mL | 0.7545 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- ACTB-1003
Catalog No.:BCC5587
CAS No.:939805-30-8
- PF-00562271
Catalog No.:BCC3684
CAS No.:939791-38-5
- [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human)
Catalog No.:BCC5719
CAS No.:93965-89-0
- Fluvastatin Sodium
Catalog No.:BCC2317
CAS No.:93957-55-2
- Fluvastatin
Catalog No.:BCC1579
CAS No.:93957-54-1
- Toonaciliatin M
Catalog No.:BCN7881
CAS No.:93930-04-2
- Hirsutanonol 5-O-glucoside
Catalog No.:BCN4485
CAS No.:93915-36-7
- FIPI
Catalog No.:BCC7721
CAS No.:939055-18-2
- 9-Oxo-2,7-bisaboladien-15-oic acid
Catalog No.:BCN4484
CAS No.:93888-59-6
- Isochamaejasmine
Catalog No.:BCN3128
CAS No.:93859-63-3
- KU-0063794
Catalog No.:BCC2484
CAS No.:938440-64-3
- ATPγS tetralithium salt
Catalog No.:BCC7855
CAS No.:93839-89-5
- p53 and MDM2 proteins-interaction-inhibitor chiral
Catalog No.:BCC1830
CAS No.:939981-37-0
- RG7112
Catalog No.:BCC1894
CAS No.:939981-39-2
- p53 and MDM2 proteins-interaction-inhibitor racemic
Catalog No.:BCC1831
CAS No.:939983-14-9
- Synephrine
Catalog No.:BCN6308
CAS No.:94-07-5
- Benzocaine
Catalog No.:BCC4636
CAS No.:94-09-7
- Propylparaben
Catalog No.:BCN8416
CAS No.:94-13-3
- Sodium 4-amiropparaty Hyalrate
Catalog No.:BCC3855
CAS No.:94-16-6
- Benzyl 4-hydroxybenzoate
Catalog No.:BCC8869
CAS No.:94-18-8
- Chlorpropamide
Catalog No.:BCC4647
CAS No.:94-20-2
- Tetracaine
Catalog No.:BCC9175
CAS No.:94-24-6
- Butylparaben
Catalog No.:BCN8418
CAS No.:94-26-8
- Benzyl nicotinate
Catalog No.:BCC8874
CAS No.:94-44-0
HNF4alpha antagonists discovered by a high-throughput screen for modulators of the human insulin promoter.[Pubmed:22840769]
Chem Biol. 2012 Jul 27;19(7):806-18.
Hepatocyte nuclear factor (HNF)4alpha is a central regulator of gene expression in cell types that play a critical role in metabolic homeostasis, including hepatocytes, enterocytes, and pancreatic beta cells. Although fatty acids were found to occupy the HNF4alpha ligand-binding pocket and were proposed to act as ligands, there is controversy about both the nature of HNF4alpha ligands as well as the physiological role of the binding. Here, we report the discovery of potent synthetic HNF4alpha antagonists through a high-throughput screen for effectors of the human insulin promoter. These molecules bound to HNF4alpha with high affinity and modulated the expression of known HNF4alpha target genes. Notably, they were found to be selectively cytotoxic to cancer cell lines in vitro and in vivo, although in vivo potency was limited by suboptimal pharmacokinetic properties. The discovery of bioactive modulators for HNF4alpha raises the possibility that diseases involving HNF4alpha, such as diabetes and cancer, might be amenable to pharmacologic intervention by modulation of HNF4alpha activity.